Patents by Inventor Guoqiang Wang

Guoqiang Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170346679
    Abstract: The present disclosure provides a method and system for reconstructing UAV formation communication topology based on minimum cost arborescence, the method comprising: monitoring broadcast communication channel, and judging whether communication failure occurs in UAV in formation; modifying formation communication diagram according to the type of communication failure when communication failure occurs in the UAV; calculating minimum cost arborescence of modified formation communication diagram, and reconstructing UAV formation communication topology according to calculation results.
    Type: Application
    Filed: March 16, 2017
    Publication date: November 30, 2017
    Applicant: Hefei University of Technology
    Inventors: He Luo, Guoqiang Wang, Xiaoxuan Hu, Huawei MA, Peng Jin, Wei Xia
  • Publication number: 20170347285
    Abstract: A method and a system for reoptimizing unmanned aerial vehicle formation communication topology based on minimum cost arborescence are used for optimizing reconstructed UAV formation communication topology after a communication failure occurs on the UAVs in the formation. The method includes calculating a first communication cost of the reconstructed UAV formation communication topology; comparing the first communication cost with a target communication cost for the minimum cost arborescence of the formation communication diagram under a predetermined state; when the first communication cost is greater than the target communication cost for the minimum cost arborescence of the formation communication diagram under the predetermined state, optimizing the reconstructed UAV formation communication topology through a predetermined strategy.
    Type: Application
    Filed: May 30, 2017
    Publication date: November 30, 2017
    Inventors: He LUO, Guoqiang WANG, Xiaoxuan HU, Huawei MA, Peng JIN, Wei XIA
  • Publication number: 20170334894
    Abstract: The present invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.
    Type: Application
    Filed: May 17, 2017
    Publication date: November 23, 2017
    Inventors: Yat Sun Or, Yong He, Ruichao Shen, Xuechao Xing, Brett Granger, Bin Wang, Jun Ma, Jing He, Jiang Long, Guoqiang Wang
  • Publication number: 20170334893
    Abstract: The present invention provides compounds of Formula I: pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.
    Type: Application
    Filed: May 17, 2017
    Publication date: November 23, 2017
    Inventors: Yat Sun Or, Jun Ma, Bin Wang, Yong He, Xuechao Xing, Ruichao Shen, Brett Granger, Jing He, Jiang Long, Guoqiang Wang
  • Publication number: 20170339228
    Abstract: An anchor server in an information-centric network (ICN) receives registration and deregistration requests from one or more producers in the ICN. In response to a producer initially registering, the anchor server stores records associating the producer with content available from the producer via a first point of attachment. In response to the producer deregistering, the records are marked as deactivated. While the records are deactivated, requests for the content from consumers may be queued. In response to the producer reregistering as being connected to the ICN via a second point of attachment, the queued requests are forwarded to the producer via the second point of attachment.
    Type: Application
    Filed: May 19, 2016
    Publication date: November 23, 2017
    Inventors: Aytac Azgin, Ravishankar Ravindran, Guoqiang Wang
  • Publication number: 20170333399
    Abstract: The present invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR and methods for their preparation and use.
    Type: Application
    Filed: May 17, 2017
    Publication date: November 23, 2017
    Inventors: Yat Sun Or, Xuechao Xing, Ruichao Shen, Bin Wang, Brett Granger, Jun Ma, Jing He, Jiang Long, Yong He, Guoqiang Wang
  • Publication number: 20170304272
    Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.
    Type: Application
    Filed: April 26, 2017
    Publication date: October 26, 2017
    Inventors: Yat Sun Or, Bin Wang, Xuechao Xing, Ruichao Shen, Brett Granger, Jun Ma, Jing He, Yong He, Jiang Long, Guoqiang Wang
  • Publication number: 20170304271
    Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.
    Type: Application
    Filed: April 26, 2017
    Publication date: October 26, 2017
    Inventors: Yat Sun Or, Ruichao Shen, Xuechao Xing, Brett Granger, Bin Wang, Jun Ma, Jing He, Yong He, Jiang Long, Guoqiang Wang
  • Publication number: 20170304270
    Abstract: The present invention provides compounds of Formula I: pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.
    Type: Application
    Filed: April 26, 2017
    Publication date: October 26, 2017
    Inventors: Yat Sun Or, Brett Granger, Ruichao Shen, Xuechao Xing, Bin Wang, Jun Ma, Jing He, Jiang Long, Yong He, Guoqiang Wang
  • Patent number: 9774610
    Abstract: A method comprises accessing, by a processor of a machine, an encrypted data packet from a first source, the encrypted data packet being accompanied by a signature of the first source. The processor further accesses parameters from a second source and verifies, based on the signature of the first source and the parameters, that the encrypted data packet was generated by the first source. The method further comprises decrypting, based on the verification that the encrypted data packet was generated by the first source, by the processor, the encrypted data packet.
    Type: Grant
    Filed: July 28, 2015
    Date of Patent: September 26, 2017
    Assignee: Futurewei Technologies, Inc.
    Inventors: Qingji Zheng, Guoqiang Wang
  • Publication number: 20170240587
    Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR and/or TGR5.
    Type: Application
    Filed: February 22, 2017
    Publication date: August 24, 2017
    Inventors: Yat Sun Or, Jing He, Guoqiang Wang, Xuechao Xing
  • Publication number: 20170240586
    Abstract: The present invention provides compounds of Formula I: pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR and/or TGR5.
    Type: Application
    Filed: February 22, 2017
    Publication date: August 24, 2017
    Inventors: Yat Sun Or, Xuechao Xing, Guoqiang Wang, Ruichao Shen, Jing He
  • Publication number: 20170240585
    Abstract: The present invention provides compounds of Formula (I) or Formula (II): pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR and/or TGR5.
    Type: Application
    Filed: February 22, 2017
    Publication date: August 24, 2017
    Inventors: Guoqiang Wang, Yat Sun Or, Jiang Long, Guoyou Xu, Peng Dai, Ruichao Shen, Xuechao Xing, Jing He
  • Patent number: 9718851
    Abstract: The present invention provides nucleoside phosphoramidate compounds of Formula I, where R1, R2a, R2b, R4, R5a, R5b, Rb5, Rb6 and D are as defined herein. The invention further includes pharmaceutical compositions comprising a compound of Formula I, methods of use of these compounds for treating a viral infection, and methods of producing these compounds.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: August 1, 2017
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Jay R. Luly, Bin Wang, Guoqiang Wang, Yat Sun Or
  • Patent number: 9669095
    Abstract: The present invention relates to novel cyclosporine analogs having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporine analog compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.
    Type: Grant
    Filed: November 3, 2015
    Date of Patent: June 6, 2017
    Assignee: ENANTA PHARMACEUTICALS, INC.
    Inventors: Guoqiang Wang, In Jong Kim, Yat Sun Or
  • Patent number: 9616099
    Abstract: The present invention relates to novel cyclosporine analogs having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporine analog compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: April 11, 2017
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Yat Sun Or, Guoqiang Wang, Jiang Long, In Jong Kim
  • Publication number: 20170088583
    Abstract: The present invention discloses compounds of Formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: October 6, 2016
    Publication date: March 30, 2017
    Inventors: Yat Sun Or, Jun Ma, Guoqiang Wang, Jiang Long, Bin Wang
  • Patent number: 9603895
    Abstract: The present invention relates to cyclosporin analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporin analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.
    Type: Grant
    Filed: September 2, 2015
    Date of Patent: March 28, 2017
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Yat Sun Or, Guoqiang Wang, Jiang Long, Xuri Gao
  • Publication number: 20170064028
    Abstract: A network element, comprising a memory that comprises a pending interest table, a receiver operably coupled to the memory and configured to receive an extended interest message in an information centric network, a processor operably coupled to the receiver and memory and configured to determine a desired content according to the extended interest message, determine a prescribed quality of service (QoS) level requested for delivering the desired content to a client, record a path state in the memory, record a return route in the pending interest table of the memory, and determine a next location in the information centric network to which the extended interest message is to be sent, and a transmitter operably coupled to the processor and configured to transmit the extended interest message to the next location in the information centric network.
    Type: Application
    Filed: August 26, 2015
    Publication date: March 2, 2017
    Inventors: Cedric Westphal, Guoqiang Wang
  • Publication number: 20170034186
    Abstract: A method comprises accessing, by a processor of a machine, an encrypted data packet from a first source, the encrypted data packet being accompanied by a signature of the first source. The processor further accesses parameters from a second source and verifies, based on the signature of the first source and the parameters, that the encrypted data packet was generated by the first source. The method further comprises decrypting, based on the verification that the encrypted data packet was generated by the first source, by the processor, the encrypted data packet.
    Type: Application
    Filed: July 28, 2015
    Publication date: February 2, 2017
    Inventors: Qingji Zheng, Guoqiang Wang